287 related articles for article (PubMed ID: 33534834)
1. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
2. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
[TBL] [Abstract][Full Text] [Related]
3. Robust envelope exchange platform for oncolytic measles virus.
Neault S; Bossow S; Achard C; Bell JC; Diallo JS; Leber MF; Ungerechts G
J Virol Methods; 2022 Apr; 302():114487. PubMed ID: 35104497
[TBL] [Abstract][Full Text] [Related]
4. Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins.
Muñoz-Alía MA; Russell SJ
Viruses; 2019 Jul; 11(8):. PubMed ID: 31357579
[TBL] [Abstract][Full Text] [Related]
5. Functional and structural interactions between measles virus hemagglutinin and CD46.
Nussbaum O; Broder CC; Moss B; Stern LB; Rozenblatt S; Berger EA
J Virol; 1995 Jun; 69(6):3341-9. PubMed ID: 7745681
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism by which residues at position 481 and 546 of measles virus hemagglutinin protein define CD46 receptor binding using a molecular docking approach.
Sajjadi S; Shirode A; Vaidya SR; Cherian SS
Comput Biol Chem; 2019 Jun; 80():384-389. PubMed ID: 31112822
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
Liu C; Russell SJ; Peng KW
Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
11. Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.
Muñoz-Alía MÁ; Muller CP; Russell SJ
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356529
[TBL] [Abstract][Full Text] [Related]
12. Antibody neutralization of retargeted measles viruses.
Lech PJ; Pappoe R; Nakamura T; Tobin GJ; Nara PL; Russell SJ
Virology; 2014 Apr; 454-455():237-46. PubMed ID: 24725950
[TBL] [Abstract][Full Text] [Related]
13. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
14. An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
Lal S; Carrera D; Phillips JJ; Weiss WA; Raffel C
Neuro Oncol; 2018 Nov; 20(12):1606-1615. PubMed ID: 29912438
[TBL] [Abstract][Full Text] [Related]
15. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
17. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P; Dispenzieri A; Galanis E
Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
[TBL] [Abstract][Full Text] [Related]
18. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
19. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
Hartkopf AD; Bossow S; Lampe J; Zimmermann M; Taran FA; Wallwiener D; Fehm T; Bitzer M; Lauer UM
Gynecol Oncol; 2013 Aug; 130(2):362-8. PubMed ID: 23676551
[TBL] [Abstract][Full Text] [Related]
20. Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
Lühl NC; Zirngibl F; Dorneburg C; Wei J; Dahlhaus M; Barth TF; Meyer LH; Queudeville M; Eckhoff S; Debatin KM; Beltinger C
Haematologica; 2014 Jun; 99(6):1050-61. PubMed ID: 24700491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
